In this study, we evaluated the immunostimulatory effect of silk peptide in subjects with peripheral blood leukocyte levels of 4–8 × 10 3 /μl by a randomized, double-blind, placebo-controlled clinical trial. The subjects were randomly assigned to one of two groups, the placebo control or silk peptide intervention group, for 8 weeks. As a result, evaluation of efficacy in 97 subjects showed no significant difference between the groups in immunostimulatory parameters. However, after separate analysis of 61 non-season influenza vaccine subjects, the natural killer cell activity (%) with an effector cell: target cell (E: T) ratio of 10:1 was increased significantly from 30.7 ± 2.28% at week 0 to 41.8 ± 2.71% at week 8 (p < 0.01) in the silk peptide groups. In addition, IL-2, IL-12, and IFN-γ levels were increased in the silk peptide group and decreased in the placebo group. These results suggested that silk peptide is effective for enhancing immune activity.
All Science Journal Classification (ASJC) codes
- Food Science
- Medicine (miscellaneous)
- Nutrition and Dietetics